Programm zur Förderung von Forschung, Innovation und Technologien (ProFIT Brandenburg), Nr. 8016982, 8016983
The main goal of the project is the development and characterization of the novel DPP3 neutralizing therapeutic antibody Procizumab. Within the scope of the project, we develop a GMP conform cell line for Procizumab production and characterize the antibody with different preclinical and biochemical methods. In addition, we develop different immunoassays to detect DPP3 and Procizumab in different samples and matrices.